Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours

Acta Oncologica

Volumn 49, Issue 6, 2010, Pages 740-756

  Janson, Eva Tiensuu ^a   Sørbye, Halfdan ^b   Welin, Staffan ^a   Federspiel, Birgitte ^c   Grønbæk, Henning ^d   Hellman, Per ^e   Mathisen, Øystein ^f   Mortensen, Jann ^c   Sundin, Anders ^g   Thiis Evensen, Espen ^f   Välimäki, Matti J ^h   Öberg, Kjell ^a   Knigge, Ulrich ^c  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e UPPSALA UNIVERSITY   (Sweden)

^f OSLO UNIVERSITY HOSPITAL   (Norway)

^g KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^h HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANGIOPEPTIN; BIOCHEMICAL MARKER; CAPECITABINE; CARBOPLATIN; CISPLATIN; DOXORUBICIN; ETOPOSIDE; EVEROLIMUS; FLUOROURACIL; GEMCITABINE; INDIUM 111; INTERFERON; LANREOTIDE AUTOGEL; LANREOTIDE PR; LUTETIUM 177; MULTIFERON; OCTREOTIDE; PARACETAMOL; PASIREOTIDE; PEG INTRONA; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN; SUNITINIB; TEMOZOLOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; YTTRIUM 90;

ABDOMINAL CRAMP; ANTINEOPLASTIC ACTIVITY; APPENDECTOMY; APPENDIX NEUROENDOCRINE TUMOR; BLOOD TOXICITY; BONE MARROW DEPRESSION; BONE SCINTISCANNING; BRADYCARDIA; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER THERAPY; CARCINOID; CARCINOID SYNDROME; CARDIOTOXICITY; CHEMICAL ANALYSIS; CHRONIC FATIGUE SYNDROME; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; COLON NEUROENDOCRINE TUMOR; DEPRESSION; DIAGNOSTIC PROCEDURE; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG FORMULATION; DRUG MECHANISM; DRUG RELEASE; DUODENAL NEUROENDOCRINE TUMOR; ENDOCRINE TUMOR; ESOPHAGEAL NEUROENDOCRINE TUMOR; EXTERNAL BEAM RADIOTHERAPY; FEVER; FLATULENCE; FLU LIKE SYNDROME; FOLLOW UP; GASTRIC NEUROENDOCRINE TUMOR; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; GASTROINTESTINAL TUMOR; GOBLET CELL CARCINOID; HEMICOLECTOMY; HISTOPATHOLOGY; HUMAN; HYPERGLYCEMIA; HYPOCALCEMIA; HYPOGLYCEMIA; IMAGING; LIVER METASTASIS; LYMPH NODE DISSECTION; METASTASIS; MYOSITIS; NAUSEA; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; NEUROLOGIC DISEASE; PANCREAS CANCER; PANCREATIC NEUROENDOCRINE TUMOR; PERIPHERAL NEUROPATHY; POORLY DIFFERENTIATED ENDOCRINE CARCINOMA; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RADIOISOTOPE THERAPY; RADIOLOGICAL PROCEDURES; RECTAL NEUROENDOCRINE TUMOR; REVIEW; SCINTIGRAPHY; SIDE EFFECT; SMALL INTESTINE CANCER; SUBCUTANEOUS NODULE; THROMBOCYTOPENIA; THYROIDITIS; TREATMENT RESPONSE; TUBULAR CARCINOID; TUMOR BIOPSY; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT REDUCTION;

ALGORITHMS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DENMARK; FINLAND; GASTROINTESTINAL NEOPLASMS; HUMANS; NEUROENDOCRINE TUMORS; NORWAY; PANCREATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; SWEDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 77954520495     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2010.492791     Document Type: Review

References (61)

1. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after "carcinoid": Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-3072
2. Capella C, Heitz PU, Hofler H, Solcia E, Kloppel G. Revised classifi cation of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch 1995;425:547-560
3. Kloppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: The WHO classifi cation. Ann N Y Acad Sci 2004;1014:13-27.
4. Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, et al. TNM staging of foregut (neuro)endocrine tumors: A consensus proposal including a grading system. Virchows Arch 2006;449:395-401.
5. Rindi G, Kloppel G, Couvelard A, Komminoth P, Korner M, Lopes JM, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: A consensus proposal including a grading system. Virchows Arch 2007;451:757-762
6. Cunningham JL, Grimelius L, Sundin A, Agarwal S, Janson ET. Malignant ileocaecal serotonin-producing carcinoid tumours: The presence of a solid growth pattern and/or Ki67 index above 1% identifies patients with a poorer prognosis. Acta Oncol 2007;46:747-756
7. de Herder WW. Biochemistry of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007;21:33-41.
8. Helle KB, Corti A, Metz-Boutigue MH, Tota B. The endocrine role for chromogranin A: A prohormone for peptides with regulatory properties. Cell Mol Life Sci 2007; 64:2863-2886
9. Welin S, Stridsberg M, Cunningham J, Granberg D, Skogseid B, Oberg K, et al. Elevated plasma chromogranin A is the fi rst indication of recurrence in radically operated midgut carcinoid tumors. Neuroendocrinology 2009;89:302-307
10. Tropea F, Baldari S, Restifo G, Fiorillo MT, Surace P, Herberg A. Evaluation of chromogranin A expression in patients with non-neuroendocrine tumours. Clin Drug Investig 2006;26:715-722
11. Thoeni RF, Mueller-Lisse UG, Chan R, Do NK, Shyn PB. Detection of small, functional islet cell tumors in the pancreas: Selection of MR imaging sequences for optimal sensitivity. Radiology 2000;214:483-490
12. Dromain C, de Baere T, Lumbroso J, Caillet H, Laplanche A, Boige V, et al. Detection of liver metastases from endocrine tumors: A prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol 2005;23:70-78
13. Mork H, Ignee A, Schuessler G, Ott M, Dietrich CF. Analysis of neuroendocrine tumour metastases in the liver using contrast enhanced ultrasonography. Scand J Gastroenterol 2007;42:652-662
14. Sundin A, Vullierme MP, Kaltsas G, Plockinger U. ENETS Consensus Guidelines for the standards of care in neuroendocrine tumors: Radiological examinations. Neuroendocrinology 2009;90:167-183
15. Rappeport ED, Hansen CP, Kjaer A, Knigge U. Multidetector computed tomography and neuroendocrine pancreaticoduodenal tumors. Acta Radiol 2006;47:248-256
16. Kwekkeboom DJ, Krenning EP, Scheidhauer K, Lewington V, Lebtahi R, Grossman A, et al. ENETS Consensus Guidelines for the standards of care in neuroendocrine tumors: Somatostatin receptor imaging with (111)In-pentetreotide. Neuroendocrinology 2009;90:184-189
17. Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: Comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007;48:508-518
18. Orlefors H, Sundin A, Garske U, Juhlin C, Oberg K, Skogseid B, et al. Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: Comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab 2005;90:3392-3400
19. Koopmans KP, Neels OC, Kema IP, Elsinga PH, Sluiter WJ, Vanghillewe K, et al. Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenylalanine and 11C-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol 2008;26:1489-1495
20. Binderup T, Knigge U, Loft A, Federspiel B, Kjaer A. 18F-fl uorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res 2010;16:978-985
21. Hellman P, Lundstrom T, Ohrvall U, Eriksson B, Skogseid B, Oberg K, et al. Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases. World J Surg 2002;26:991-997
22. Hodul PJ, Strosberg JR, Kvols LK. Aggressive surgical resection in the management of pancreatic neuroendocrine tumors: When is it indicated? Cancer Control 2008;15: 314-321
23. Delaunoit T, Neczyporenko F, Rubin J, Erlichman C, Hobday TJ. Medical management of pancreatic neuroendocrine tumors. Am J Gastroenterol 2008;103:475 - 83; quiz 84.
24. Vilar E, Salazar R, Perez-Garcia J, Cortes J, Oberg K, Tabernero J. Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. Endocr Relat Cancer 2007;14:221-232
25. Eriksson B, Annibale B, Bajetta E, Mitry E, Pavel M, Platania M, et al. ENETS Consensus Guidelines for the standards of care in neuroendocrine tumors: Chemotherapy in patients with neuroendocrine tumors. Neuroendocrinology 2009;90:214-219
26. Ekeblad S, Sundin A, Janson ET, Welin S, Granberg D, Kindmark H, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007;13:2986-2991
27. Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006;24:401-406
28. Strosberg JR, Choi J, Gardner N, Kvols L. First-line treatment of metastatic pancreatic endocrine carcinomas with capecitabine and temozolomide. J Clin Oncol 2008;26(ASCO Annual Meeting Proceedings Part 1, 15S):Abstract 4612.
29. Isacoff WH, Moss, RA, Pecora, AL, Fine, L. Temozolomide/ capcitabine therapy for metastatic neuroendocrine tumors of the pancreas. J Clin Oncol 2006;24(ASCO Annual Meeting Proceedings Part 1, 18S):Abstract 14023.
30. Fjallskog ML, Granberg DP, Welin SL, Eriksson C, Oberg KE, Janson ET, et al. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 2001;92:1101-1107
31. Moertel CG, Kvols LK, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991;68:227-232
32. Mitry E, Baudin E, Ducreux M, Sabourin JC, Rufi e P, Aparicio T, et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 1999;81:1351-1355
33. Fazio N, de Braud F, Delle Fave G, Oberg K. Interferonalpha and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: Single agent or combination? Ann Oncol 2007;18:13-19
34. Plockinger U, Wiedenmann B. Neuroendocrine tumors. Biotherapy. Best Pract Res Clin Endocrinol Metab 2007; 21:145-162
35. Pavel ME, Baum U, Hahn EG, Schuppan D, Lohmann T. Effi cacy and tolerability of pegylated IFN-alpha in patients with neuroendocrine gastroenteropancreatic carcinomas. J Interferon Cytokine Res 2006;26:8-13.
36. Modlin IM, Pavel M, Kidd M, Gustafsson BI. Review article: Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 2010;31:169-188
37. Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group. J Clin Oncol 2009;27:4656-4663
38. van Essen M, Krenning EP, Kam BL, de Jong M, Valkema R, Kwekkeboom DJ. Peptide-receptor radionuclide therapy for endocrine tumors. Nat Rev Endocrinol 2009;5:382-393
39. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: Toxicity, effi cacy, and survival. J Clin Oncol 2008;26:2124-2130
40. Toumpanakis CG, Caplin ME. Molecular genetics of gastroenteropancreatic neuroendocrine tumors. Am J Gastroenterol 2008;103:729-732
41. Boikos SA, Stratakis CA. Carney complex: Pathology and molecular genetics. Neuroendocrinology 2006;83:189-199
42. Ku GY, Minsky BD, Rusch VW, Bains M, Kelsen DP, Ilson DH. Small-cell carcinoma of the esophagus and gastroesophageal junction: Review of the Memorial Sloan-Kettering experience. Ann Oncol 2008;19:533-537
43. Fykse V, Sandvik AK, Qvigstad G, Falkmer SE, Syversen U, Waldum HL. Treatment of ECL cell carcinoids with octreotide LAR. Scand J Gastroenterol 2004;39:621-628
44. Berna MJ, Hoffmann KM, Long SH, Serrano J, Gibril F, Jensen RT. Serum gastrin in Zollinger-Ellison syndrome: II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. Evaluation of diagnostic criteria, proposal of new criteria, and correlations with clinical and tumoral features. Medicine (Baltimore) 2006;85:331-364
45. Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): Incidence, prognosis and recent trend toward improved survival. Ann Oncol 2008;19:1727-1733
46. de Herder WW, Niederle B, Scoazec JY, Pauwels S, Kloppel G, Falconi M, et al. Well-differentiated pancreatic tumor/carcinoma: Insulinoma. Neuroendocrinology 2006;84:183-188
47. Anderson MA, Carpenter S, Thompson NW, Nostrant TT, Elta GH, Scheiman JM. Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am J Gastroenterol 2000;95: 2271-2277
48. Kauhanen S, Seppanen M, Minn H, Gullichsen R, Salonen A, Alanen K, et al. Fluorine-18-L-dihydroxyphenylalanine (18F-DOPA) positron emission tomography as a tool to localize an insulinoma or beta-cell hyperplasia in adult patients. J Clin Endocrinol Metab 2007;92:1237-1244
49. Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: A phase II trial. J Clin Oncol 2010;28:69-76.
50. Raymond E, Niccoli-Sire P. Bang Y-J, Borbath I, Lombard- Bohas C, Valle J, et al. Updated results of the phase III trial of sunitinib versus placebo for treatment of advanced pancreatic neuroendocrine tumors. Gastrointestinal Cancer Symposium 2010:Abstract 127.
51. Ekeblad S, Skogseid B, Dunder K, Oberg K, Eriksson B. Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res 2008;14:7798-7803
52. Kolby L, Persson G, Franzen S, Ahren B. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br J Surg 2003;90:687-693
53. McGory ML, Maggard MA, Kang H, O'Connell JB, Ko CY. Malignancies of the appendix: Beyond case series reports. Dis Colon Rectum 2005;48:2264-2271
54. Tang LH, Shia J, Soslow RA, Dhall D, Wong WD, O'Reilly E, et al. Pathologic classifi cation and clinical behavior of the spectrum of goblet cell carcinoid tumors of the appendix. Am J Surg Pathol 2008;32:1429-1443
55. Formica V, Wotherspoon A, Cunningham D, Norman AR, Sirohi B, Oates J, et al. The prognostic role of WHO classifi cation, urinary 5-hydroxyindoleacetic acid and liver function tests in metastatic neuroendocrine carcinomas of the gastroenteropancreatic tract. Br J Cancer 2007;96: 1178-1182
56. Brenner B, Tang LH, Klimstra DS, Kelsen DP. Small-cell carcinomas of the gastrointestinal tract: A review. J Clin Oncol 2004;22:2730-2739
57. Shia J, Tang LH, Weiser MR, Brenner B, Adsay NV, Stelow EB, et al. Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity? Am J Surg Pathol 2008;32:719-731
58. Azimuddin K, Chamberlain RS. The surgical management of pancreatic neuroendocrine tumors. Surg Clin North Am 2001;81:511-525
59. Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG. Surgical treatment of neuroendocrine metastases to the liver: A plea for resection to increase survival. J Am Coll Surg 2003;197:29-37.
60. Frilling A, Li J, Malamutmann E, Schmid KW, Bockisch A, Broelsch CE. Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease. Br J Surg 2009;96:175-184
61. Eriksson J, Stalberg P, Nilsson A, Krause J, Lundberg C, Skogseid B, et al. Surgery and radiofrequency ablation for treatment of liver metastases from midgut and foregut carcinoids and endocrine pancreatic tumors. World J Surg 2008;32:930-938